Anemia and Iron Deficiency: What Every Cardiologist Needs to Know
|
|
- Loraine Wilkerson
- 5 years ago
- Views:
Transcription
1 6th Saudi HF Group Symposium Riyadh - December 8-9, 2017 Anemia and Iron Deficiency: What Every Cardiologist Needs to Know Ammar Chaudhary MBChB, FRCPC Consultant Cardiologist Advanced Heart Failure Department of Cardiology King Faisal Specialist Hospital and Research Center Jeddah, Saudi Arabia
2 Outline Associations between HF, anemia, and iron deficiency Evidence for treating anemia and iron deficiency Guideline recommendations Ongoing studies
3 Extent of the Problem: Anemia in Ambulatory HF Patients Yi-Da Tang, et al. Heart Fail Rev (2008) 13:
4 Anemia in Advanced HF Patients Yi-Da Tang, et al. Heart Fail Rev (2008) 13:
5 Anemia Across RCTs of HFrEF Therapies Yi-Da Tang, et al. Heart Fail Rev (2008) 13:
6 Anemia in Ambulatory HF Patients Yi-Da Tang, et al. Heart Fail Rev (2008) 13:
7 Anemia in Advanced HF Patients Yi-Da Tang, et al. Heart Fail Rev (2008) 13:
8 Anemia Across RCTs of HFrEF Therapies Yi-Da Tang, et al. Heart Fail Rev (2008) 13:
9 Anemia in Ambulatory HF Patients Prevalence 15% - 55% ~ 31% Yi-Da Tang, et al. Heart Fail Rev (2008) 13:
10 Anemia in Advanced HF Patients Prevalence 15% - 47% ~ 35% Yi-Da Tang, et al. Heart Fail Rev (2008) 13:
11 Anemia Across RCTs of HFrEF Therapies Prevalence 4% - 49% ~ 11% Yi-Da Tang, et al. Heart Fail Rev (2008) 13:
12 Extent of the Problem 50% of Medicare beneficiaries with HF > 65 yrs are anemic ^Bhatia RS, et al. N Engl J Med 2006;355:260-9
13 Extent of the Problem 50% of Medicare beneficiaries with HF > 65 yrs are anemic HB < 10 g/dl 9.9% HFrEF vs. 21.1% HFpEF, p < 0.001^ ^Bhatia RS, et al. N Engl J Med 2006;355:260-9
14 Extent of the Problem 50% of Medicare beneficiaries with HF > 65 yrs are anemic HB < 10 g/dl 9.9% HFrEF vs. 21.1% HFpEF, p < 0.001^ Factors: Age, heart failure stage, comorbidities (DM, CKD) ^Bhatia RS, et al. N Engl J Med 2006;355:260-9
15 Prognostic Implications of Anemia in HF HR Pre-Tx HF Patients Yi-Da Tang, et al. Heart Fail Rev (2008) 13:
16 Prognostic Implications of Anemia in HF HR RCTs of ACEi, ARB, BB Yi-Da Tang, et al. Heart Fail Rev (2008) 13:
17 Prognostic Implications of Anemia in HF
18 Why Anemia Occurs in HF Dilutional anemia Anemia in HF
19 Why Anemia Occurs in HF Dilutional anemia RAASi Anemia in HF
20 Why Anemia Occurs in HF Dilutional anemia RAASi Anemia in HF CKD
21 Why Anemia Occurs in HF Dilutional anemia RAASi Anemia in HF Iron Deficiency CKD
22 Why Anemia Occurs in HF Dilutional anemia Hepcidin RAASi Anemia in HF Iron Deficiency CKD
23 Why Anemia Occurs in HF Inhibited iron absorption Dilutional anemia & iron release from RES Hepcidin RAASi Anemia in HF IL-6 Iron Deficiency CKD D Angelo, et al. Blood Res 2013;48:10-5
24 Summary of Erythropoetin Agents in HF Anand I, et al. J Am Coll Cardiol 2008;52:501 11
25 Summary of Erythropoetin Agents in HF Anand I, et al. J Am Coll Cardiol 2008;52:501 11
26 Darbopoetin-alpha for Anemia in HF N = 2278 Patients: LVEF 40%, NYHA II HB 9-12 g/dl, Intervention: darbapoetin alfa 0.75 mcg / kg weekly to HB > 13 then monthly Outcome: All-cause mortality or first HF hospitalization Swedberg K, et al. N Engl J Med 2013;368:1210-9
27 Darbopoetin-alpha for Anemia in HF N = 2278 Patients: LVEF 40%, NYHA II HB 9-12 g/dl, Intervention: darbapoetin alfa 0.75 mcg / kg weekly to HB > 13 then monthly Outcome: All-cause mortality or first HF hospitalization Any thombo-embolic event 4.5% vs 2.4%, p = Swedberg K, et al. N Engl J Med 2013;368:1210-9
28 Erythropoiesis-Stimulating Agents in HF Guideline Recommendations COR, LOE ACC 2017 Update of ACC 2013 HF Guidelines Class III, LOE B In patients with HF and anemia, erythropoietin stimulating agents should not be used to improve morbidity and mortality COR, LOE Canadian Cardiovascular Guidelines 2017 Update Strong Recommendation; High-Quality We recommend erythropoiesis-stimulating agents (ESAs) not be routinely used to treat anemia in HF Evidence
29 Why Anemia Occurs in HF Inhibited iron absorption Dilutional anemia & iron release from RES Hepcidin RAASi Anemia in HF IL-6 Iron Deficiency CKD D Angelo, et al. Blood Res 2013;48:10-5
30 Lab Characteristics of Iron Def in HF Transferrin Sat Ferritin Hepcidin Iron Deficiency Low Low Low Anemia of Chronic Disease Low Normal/high High D Angelo, et al. Blood Res 2013;48:10-5
31 Lab Characteristics of Iron Def in HF Transferrin Sat Ferritin Hepcidin Iron Deficiency Low Low Low Anemia of Chronic Disease Anemia of Iron Low Normal/high High < 100 deficiency in Chronic Low or High Disease Tsat < 20% D Angelo, et al. Blood Res 2013;48:10-5
32
33 Iron deficiency as a Target in HF Iron is essential in hemoglobin synthesis, mitochondrial biogenesis and respiratory chain, oxidative phosphorylation, and citric acid cycle Naito Y, et al. Am J Physiol Heart Circ Physiol 2009;296:H Melenovsky V, et al., Eur J Heart Fail Apr;19(4):
34 Iron deficiency as a Target in HF Iron is essential in hemoglobin synthesis, mitochondrial biogenesis and respiratory chain, oxidative phosphorylation, and citric acid cycle In animal models, iron deficieny can precipitate neurohormonal activation, LVH, LV dilatation, severe LV dysfunction, mitochondrial swelling Naito Y, et al. Am J Physiol Heart Circ Physiol 2009;296:H Melenovsky V, et al., Eur J Heart Fail Apr;19(4):
35 Iron deficiency as a Target in HF Iron is essential in hemoglobin synthesis, mitochondrial biogenesis and respiratory chain, oxidative phosphorylation, and citric acid cycle In animal models, iron deficieny can precipitate neurohormonal activation, LVH, LV dilatation, severe LV dysfunction, mitochondrial swelling Reduced expression of tranferrin receptor (Tfr) on cardiomyocites, low myocardial iron level (by 16-29%), impaired mitochondrial function, no corrleation with anemia Naito Y, et al. Am J Physiol Heart Circ Physiol 2009;296:H Melenovsky V, et al., Eur J Heart Fail Apr;19(4):
36 Iron deficiency as a Target in HF Jankowska E, et al. Eur Heart J (2013) 34,
37 IV Iron Replacement Elemental Iron Per Dose Properties Dose Calculation Number of Clinical Trials/Pts Ferric Carboxymaltose mg Rapid replenishment Weekly Ganzoni Formula 2 (n=763) Iron Sucrose mg No test dose Ganzoni Forumla 200 mg weekly 7 (n=136) Iron Dextran 20 mg / kg over 4-6 hrs Test dose required Anaphylaxis risk max 100 mg daily Ganzoni Formula 1 Total Iron Deficit (Ganzoni s formula) = Weight x (Target Hb in g/dl - Actual Hb in g/dl) x Iron Stores Melenovsky V, et al., Eur J Heart Fail Apr;19(4):
38 Iron Deficiency and Anemia in HF FAIR-HF (NEJM 2009) CONFIRM-HF (EHJ 2015) N 459 (2:1) 304 (1:1) Patients NYHA II/III (80%), LVEF < 45, HB (11.9), Ferritin <100 ng/ml or (52) + Tsat <20% (avg 17) NYHA II/III (50%), LVEF < 45, BNP> 100 pg/ml (PBNP >400), Ferritin <100 ng/ml or Tsat <20%, HB <15 g/dl Intervention IV Ferric Carboxymaltose (correction + maintenance) IV Ferric Carboxymaltose (correction + maintenance) Outcome Primary: Week 24 NYHA class, PGA Secondary: KCCQ, 6 MWT Primary: 6MWT distance at 24 wks Sec: NYHA, PGA, KCCQ Anker SD, et al. N Engl J Med 2009;361: Ponikowski P, et al. Eur Heart J Mar 14;36(11):657-68
39 Iron Deficiency and Anemia in HF FAIR-HF (NEJM 2009) CONFIRM-HF (EHJ 2015) N 459 (2:1) 304 (1:1) Patients NYHA II/III (80%), LVEF < 45, HB (11.9), Ferritin <100 ng/ml or (52) + Tsat <20% (avg 17) NYHA II/III (50%), LVEF < 45, BNP> 100 pg/ml (PBNP >400), Ferritin <100 ng/ml or Tsat <20%, HB <15 g/dl Intervention Outcome IV Ferric Carboxymaltose (correction + maintenance) Primary: Week 24 NYHA class, PGA Secondary: KCCQ, 6 MWT IV Ferric Carboxymaltose (correction + maintenance) Median 1500 mg Primary: 6MWT distance at 24 wks Sec: NYHA, PGA, KCCQ Anker SD, et al. N Engl J Med 2009;361: Ponikowski P, et al. Eur Heart J Mar 14;36(11):657-68
40 FAIR-HF Anker SD, et al. N Engl J Med 2009;361:
41 FAIR-HF Anker SD, et al. N Engl J Med 2009;361:
42 Iron Deficiency and Anemia in HF FAIR-HF 47% NYHA I or II vs. 30% in the placebo group (OR of improvement by one class, 2.40; 95% CI, 1.55 to 3.71; P<0.001 Hospitalizations HR % CI, 0.25 to 1.09; P = 0.08 Anker SD, et al. N Engl J Med 2009;361:
43
44 Iron Deficiency and Anemia in HF CONFIRM HF HR for hospitalizations 0.39 ( ), p=0.009 Ponikowski P, et al. Eur Heart J Mar 14;36(11):657-68
45 van Veldhuisen D, et al. Circulation. 2017;136:
46 Anker S, et al. Eur J Heart Fail Apr 24 van Veldhuisen D, et al. Circulation. 2017;136:
47 Meta-analysis Anker S, et al. Eur J Heart Fail Apr 24
48 van Veldhuisen D, et al. Circulation. 2017;136: Anker S, et al. Eur J Heart Fail Apr 24 Lewis G, et al. JAMA. 2017;317(19):
49 Iron Deficiency and Anemia in HF: Guideline Recommendations COR, LOE ESC 2016 HF Guideilnes Intravenous FCM should be considered in symptomatic patients (serum ferritin <100 μg/l, or ferritin between Class IIa, LOE A μg/l and transferrin saturation <20%) in order to alleviate HF symptoms, and improve exercise capacity and quality of life
50 Iron Deficiency and Anemia in HF: Guideline Recommendations COR, LOE Canadian Cardiovascular Guidelines 2017 Update Strong Recommendation; Moderate-Quality Evidence We recommend that I.V. iron therapy be considered for patients with HFrEF and ID, in view of improving exercise tolerance, quality of life, and reducing HF hospitalizations
51 Iron Deficiency and Anemia in HF: Guideline Recommendations COR, LOE ACC 2017 Update of ACC 2013 HF Guidelines In patients with NYHA class II and III HF and iron deficiency Class IIb, LOE B (ferritin <100 ng/ml or 100 to 300 ng/ml if transferrin saturation is <20%), intravenous iron replacement might be reasonable to improve functional status and QoL
52 Ongoing Trials FAIR-HF2 N = 1200 Primary end-point: Composite of HF hosp and CV mortality at 1 year Start & end dates: Feb 7, October 2020 Source; VIFOR Pharma and clinicaltrials.gov
53 Ongoing Trials FAIR-HF2 N = 1200 Primary end-point: Composite of HF hosp and CV mortality at 1 year Start & end dates: Feb 7, October 2020 Affirm-AHF Hospitalized patients with AHF after initial stabilization, EF < 50% Primary end-point: Composite of HF hosp and CV mortality at 1 year Start & end dates: April 3, December 2019 Source; VIFOR Pharma and clinicaltrials.gov
54 Ongoing Trials FAIR-HF2 N = 1200 Primary end-point: Composite of HF hosp and CV mortality at 1 year Start & end dates: Feb 7, October 2020 Affirm-AHF Hospitalized patients with AHF after initial stabilization, EF < 50% Primary end-point: Composite of HF hosp and CV mortality at 1 year Start & end dates: April 3, December 2019 HEART-FID N = 3014 Stable NYHA II-IV patients on OMT, LVEF < 35% Primary end-point: Time to all-cause death, HF hospitalization at 1 yr, change in 6 MWT at 6 months Start & end dates: March 15, June 2022 Source; VIFOR Pharma and clinicaltrials.gov
55 Conclusions Anemia is common across HF patients, but is merely a marker of poor prognosis and not a legetimate therapeutic target in itself Iron deficiency is common across HF patients regardless of anemia, and is a predictor of poor survival. Pathophysiology and additional diagnostic markers are under investigation IV iron replacement, not oral iron, is associated with improved symptoms, quality of life, and likely reduced hospitalizations in symptomatic HFrEF A consensus for a strong recommendation for IV iron therapy will await ongoing clinical trials. Data is lacking for symptomatic iron-deficient HFpEF patients
Comorbidities in Heart Failure: Iron Deficiency. Ammar Chaudhary, MBChB, FRCPC King Faisal Specialist Hospital and Research Centre - Jeddah
Comorbidities in Heart Failure: Iron Deficiency Ammar Chaudhary, MBChB, FRCPC King Faisal Specialist Hospital and Research Centre - Jeddah ACC Middle East Conference 2018 Iron Deficiency in Heart Failure
More informationIron-Deficiency Anemia and Heart Failure
Iron-Deficiency Anemia and Heart Failure SUNNY LINNEBUR, PHARMD, BCPS, BCGP PROFESSOR, UNIVERSITY OF COLORADO Objectives 1. Describe the impact of iron deficiency anemia on the heart failure patient 2.
More informationIron Deficiency: New Therapeutic Target in Heart Failure. Stefan D. Anker, MD PhD
Iron Deficiency: New Therapeutic Target in Heart Failure Stefan D. Anker, MD PhD Department of Cardiology, Applied Cachexia Research, Charité Campus Virchow-Klinikum, Universitätsmedizin Berlin, Germany.
More informationDisclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17
Disclosures Advances in Chronic Heart Failure Management I have nothing to disclose Van N Selby, MD UCSF Advanced Heart Failure Program May 22, 2017 Goal statement To review recently-approved therapies
More informationAnaemia in Chronic Heart Failure
Anaemia in Chronic Heart Failure 2011 Update Piotr Ponikowski, MD, PhD, FESC Medical University, Centre for Heart Disease Clinical Military Hospital Wroclaw, Poland DECLARATION OF CONFLICT OF INTEREST
More informationDisclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017
Advances in Chronic Heart Failure Management Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017 I have nothing to disclose Disclosures 1 Goal statement To review recently-approved therapies
More informationIron deficiency in heart failure
Iron deficiency in heart failure Piotr Ponikowski, MD, PhD, FESC Department of Heart Diseases, Wroclaw Medical University Centre for Heart Diseases, Military Hospital, Wroclaw, Poland Objectives Importance
More informationEffect of ferric carboxymaltose on functional capacity in patients with heart failure and iron deficiency (CONFIRM-HF)
Effect of ferric carboxymaltose on functional capacity in patients with heart failure and iron deficiency (CONFIRM-HF) Piotr Ponikowski, Dirk J. van Veldhuisen, Josep Comin-Colet Georg Ertl, Michel Komajda,
More informationIron metabolism anemia and beyond. Jacek Lange Perm, 8 October 2016
Iron metabolism anemia and beyond Jacek Lange Perm, 8 October 2016 1 Overview 1. Iron metabolism 2. CKD Chronic Kidney Disease 3. Iron deficiency beyond anemia and CKD 4. Conclusions 2 Why iron deficiency
More informationΔιαχείριση ασθενούς με καρδιακή ανεπάρκεια και αναιμία. Βασιλική Μπιστόλα Καρδιολόγος Β Πανεπιστημιακή Καρδιολογική Κλινική Νοσοκομείο Αττικό
Διαχείριση ασθενούς με καρδιακή ανεπάρκεια και αναιμία Βασιλική Μπιστόλα Καρδιολόγος Β Πανεπιστημιακή Καρδιολογική Κλινική Νοσοκομείο Αττικό Based on WHO Definition, 9% of Adults Have Anemia: ARIC Study*
More informationSupplementary Online Content
Supplementary Online Content Lewis GD, Malhotra R, Hernandez AF, et al. Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency:
More informationThe ACC Heart Failure Guidelines
The ACC Heart Failure Guidelines Fakhr Alayoubi, Msc,R Ph President of SCCP Cardiology Clinical Pharmacist Assistant Professor At King Saud University King Khalid University Hospital Riyadh-KSA 2017 ACC/AHA/HFSA
More informationGiovambattista Desideri UO Geriatria Università dell Aquila. Iperkaliema e sideropenia nello scompenso cardiaco
Giovambattista Desideri UO Geriatria Università dell Aquila Iperkaliema e sideropenia nello scompenso cardiaco Kaplan Meier curves for overall survival in (A) men or (B) women with diffrent cancero or
More informationCardiovascular Pharmacotherapy for Heart Failure Management
Cardiovascular Pharmacotherapy for Heart Failure Management AN UPDATE OF THE LATEST RECOMMENDATIONS AND DATA By: Debby Caraballo, PharmD, PhC, BCPS, AQ-Cardiology Balloon Fiesta Symposium, Albuquerque,
More informationHFpEF, Mito or Realidad?
HFpEF, Mito or Realidad? Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Associate Chief for Academic Affairs -- Cardiology Montefiore-Einstein Medical Center Bronx, NY
More information2016 ESC Heart Failure Guidelines: what is new? Piotr Ponikowski Wroclaw, Poland
2016 ESC Heart Failure Guidelines: what is new? Piotr Ponikowski Wroclaw, Poland Disclosures Consultancy fees and speaker s honoraria from: Amgen, Servier, Novartis, Johnson & Johnson, Merck, Berlin Chemie,
More informationUPDATES IN MANAGEMENT OF HF
UPDATES IN MANAGEMENT OF HF Jennifer R Brown MD, MS Heart Failure Specialist Medstar Cardiology Associates DC ACP Meeting Fall 2017 Disclosures: speaker bureau for novartis speaker bureau for actelion
More informationA Guide to Proper Utilization of Biomarkers
A Guide to Proper Utilization of Biomarkers DR. ABEER BAKHSH CONSULTANT CARDIOLOGIST, ADVANCE HEART FAILURE KING FAHD ARMED FORCES HOSPITAL JEDDAH, SAUDI ARABIA Objective: Mechanism of myocardial injury
More informationCardiovascular effects of hemoglobin response in patients receiving epoetin alfa and oral iron in heart failure with a preserved ejection fraction
Journal of Geriatric Cardiology (2014) 11: 100 105 2014 JGC All rights reserved; www.jgc301.com Research Article Open Access Cardiovascular effects of hemoglobin response in patients receiving epoetin
More informationDISCLOSURES ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION NONE
ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION Lori M. Tam, MD Providence Heart Institute DISCLOSURES NONE 1 OUTLINE Systolic vs. Diastolic Heart Failure New
More informationIntravenous Iron: A Good Thing Made Better? Marilyn Telen, MD Wellcome Professor of Medicine Duke University
Intravenous Iron: A Good Thing Made Better? Marilyn Telen, MD Wellcome Professor of Medicine Duke University Use of IV Iron There are increasing data regarding safety of IV iron. IV iron is superior to
More informationWhat s new in the 2017 heart failure guidelines. Prof.Dr.Mehmet Birhan YILMAZ, FESC, FACC, FHFA
What s new in the 2017 heart failure guidelines Prof.Dr.Mehmet Birhan YILMAZ, FESC, FACC, FHFA Key points to remember 2017 guidelines recommend using natriuretic peptides as biomarkers to screen for heart
More informationHeart Failure Therapies State of the Art 2017
Heart Failure Therapies State of the Art 2017 Andrew J. Sauer, MD Assistant Professor Director, Center for Heart Failure Medical Director, Heart Transplantation UNOS Primary Transplant Physician asauer@kumc.edu
More informationIron, combination therapies and new drugs on horizon
Anaemia and iron deficiency in HF Iron, combination therapies and new drugs on horizon Piotr Ponikowski, MD, PhD, FESC Wroclaw Medical University Military Hospital Wroclaw, Poland Disclosure Consultancy
More informationThe Myths of Heart Failure with Preserved Ejection Fraction:
The Myths of Heart Failure with Preserved Ejection Fraction: A misunderstood disease in search of a therapy Scott D. Solomon, MD The Edward D. Frohlich Distinguished Chair Professor of Medicine Harvard
More informationHeFSSA Practitioners Program 2017 Theme The Patient Journey: Feel Good and Live Long. Case Study 2
HeFSSA Practitioners Program 2017 Theme The Patient Journey: Feel Good and Live Long Case Study 2 HEART FAILURE WITH MID-RANGE EJECTION FRACTION TREATMENT OPTIONS CLINICAL CASE MEDICAL HISTORY 59-year-old
More informationUPDATE HEART FAILURE MANAGEMENT
Save Thais from Heart Diseases 2019 UPDATE HEART FAILURE MANAGEMENT Orawan Anupraiwan, MD. Central Chest Institute of Thailand Definition of HF Heart failure is a clinical syndrome characterized by typical
More informationAnemia Management in Peritoneal Dialysis Patients Pranay Kathuria, FACP, FASN
Anemia Management in Peritoneal Dialysis Patients Pranay Kathuria, FACP, FASN Professor of Medicine Director, Division of Nephrology and Hypertension University of Oklahoma College of Medicine Definition
More informationUniversity of Groningen. Iron status and heart failure Klip, IJsbrand Thomas
University of Groningen Iron status and heart failure Klip, IJsbrand Thomas IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check
More informationStefan D. Anker, MD PhD
Drug therapy in HF &m anaging co-morbidities in HF: focus on iron deficiency -- Delhi, 07. February 2015 -- Stefan D. Anker, MD PhD Dept. für Innovative Clinical Trials Universitätsmedizin Göttingen (UMG)
More informationDiagnosis is it really Heart Failure?
ESC Congress Munich - 25-29 August 2012 Heart Failure with Preserved Ejection Fraction From Bench to Bedside Diagnosis is it really Heart Failure? Prof. Burkert Pieske Department of Cardiology Med.University
More informationPeri-Surgical Anemia and the TAVR Patient
Peri-Surgical Anemia and the TAVR Patient Kathrine P Frey, MD Fairview Southdale Hospital Director of Blood and Pre-Operative Anemia Management April, 2015 MIDWEST VALVE SYMPOSIUM, April 2015 Credentials
More informationThe NEW Heart Failure Guidelines
The NEW Heart Failure Guidelines Daily Practice HF scenario of the Case Presentations HF as a complex and heterogeneous syndrome Several proposed pathophysiological mechanisms involving the heart and the
More informationTake-home Messages from Recent Heart Failure Trials: Heart Rate as a Target
Take-home Messages from Recent Heart Failure Trials: Heart Rate as a Target JEFFREY S. BORER, M.D. Professor and Chairman, Department of Medicine and Chief, Division of Cardiovascular Medicine; Director,
More information12 th Annual Biomarkers in Heart Failure and Acute Coronary Syndromes: Diagnosis, Treatment and Devices. Heart Rate as a Cardiovascular Biomarker
12 th Annual Biomarkers in Heart Failure and Acute Coronary Syndromes: Diagnosis, Treatment and Devices Heart Rate as a Cardiovascular Biomarker Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine,
More information2017 Summer MAOFP Update
2017 Summer MAOFP Update. Cardiology Update 2017 Landmark Trials Change Practice Guidelines David J. Strobl, DO, FNLA Heart Failure: Epidemiology More than 4 million patients affected 400,000 new cases
More informationOutline. Classification by LVEF Conventional Therapy New Therapies. Ivabradine Sacubitril/valsartan
New Pharmacological Therapies for Heart Failure Mark Drazner, MD, MSc Clinical Chief of Cardiology Medical Director, CHF/VAD/Transplant James M. Wooten Chair in Cardiology UT Southwestern Medical Center
More informationSystolic and Diastolic Dysfunction: Four Upcoming Challenges
Systolic and Diastolic Dysfunction: Four Upcoming Challenges Promoting Early Detection HFrEF: Beyond Neprilysin/Enalapril HFmrEF: What Is It and How Does One Manage It? HFpEF: Etiopathogenetic Role and
More informationHeart Failure A Disease for the Internist?
Heart Failure A Disease for the Internist? Dr Chris Davidson Sussex Cardiac Centre BRIGHTON UK Hot Topics in Heart Failure Drug treatments Valsartan / neprilysin inhib Investigations BNP and others Devices
More informationHeart Failure Guidelines For your Daily Practice
Heart Failure Guidelines For your Daily Practice Juan M. Aranda, Jr., MD, FACC, FHFSA Professor of Medicine Director of Heart Failure and Cardiac Transplantation University of Florida College of Medicine
More informationRevascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing
Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing Evidence and Uncertainties Robert O. Bonow, MD, MS, MACC Northwestern University Feinberg School of Medicine
More informationHeart Failure with Preserved EF (HFPEF) Epidemiology and management
Heart Failure with Preserved EF (HFPEF) Epidemiology and management Karl Swedberg Senior Professor of Medicine Sahlgrenska Academy University of Gothenburg Gothenburg, Sweden e-mail: karl.swedberg@gu.se
More informationManagement of Stage B Heart Failure
KSC 2017 Management of Stage B Heart Failure Byung Su Yoo, MD., PhD. Division of Cardiology, Wonju College of Medicine, Yonsei University, South Korea Focused on Symptom ASLVSD, ASLVDD LVH HF progression
More informationHFpEF. April 26, 2018
HFpEF April 26, 2018 (J Am Coll Cardiol 2017;70:2476 86) HFpEF 50% or more (40-71%) of patients with CHF have preserved LV systolic function. HFpEF is an increasingly frequent hospital discharge. Outcomes
More information2017 ACC/AHA/HFSA HF guidelines. Advances in the Use of Biomarkers in Heart Failure Patients. Outline
Advances in the Use of Biomarkers in Heart Failure Patients Lori B. Daniels, MD, MAS, FACC, FAHA Professor of Medicine Director, Cardiovascular Intensive Care Unit Sulpizio Cardiovascular Center UC San
More information578 Index. Eplerenone, 7, 29, 119, 120, 126, 275, 276,
Index A AC. See Adenylate cyclase (AC) ACEI. See Angiotensin converting enzyme inhibitors (ACEI) Adenosine, 179, 180, 182 184, 191, 196 198 Adenosine A1 receptor, 179 183, 186, 190 198 Adenylate cyclase
More informationPulmonary Hypertension Due to Left Heart Disease
ACC Middle East Conference 2018 Pulmonary Hypertension Due to Left Heart Disease Ammar Chaudhary, MBChB, FRCPC Advanced Heart Failure & Transplantation King Faisal Specialist Hospital and Research Center
More informationTrial to Reduce. Aranesp* Therapy. Cardiovascular Events with
Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis,
More informationNovel aspects of anemia and iron management in renal patients with or without cardiorenal syndrome. Renal Unit, King s College Hospital, London, UK
Novel aspects of anemia and iron management in renal patients with or without cardiorenal syndrome Renal Unit, King s College Hospital, London, UK 2002 2012 Killini 2012 2008 2018 2000 2010 2004 Erythropoiesis
More informationWhat s new in 2016 Guidelines of the European Society of Cardiology? HEART FAILURE. Marc Ferrini (Lyon Fr)
What s new in 2016 Guidelines of the European Society of Cardiology? HEART FAILURE Marc Ferrini (Lyon Fr) Palermo (I) 1 04 2017 Consulting Fees, Honoraria: BAYER PHARMA BOEHRINGER INGELHEIM BRISTOL MEYERS
More informationHeart Failure. Disclosures. Objectives: 8/28/2017. This is not a virus. It doesn t go away. none
Heart Failure This is not a virus. It doesn t go away Shelley Wojtaszczyk, FNP-C, CHFN Heart Failure Program Coordinator Mercy Hospital of Buffalo none Disclosures Objectives: Defining and identifying
More informationUNDERSTANDING BLOOD TESTS
UNDERSTANDING BLOOD TESTS Parminder Chaggar Cardiology SpR Northern General Hospital Sheffield Conflict of Interest: Nil OVERVIEW Monitoring drug titration Markers of risk Iron deficiency Thyroid disease
More informationSGK 2016 Session: Postgraduate Course in Heart Failure Lausanne, 15. June 2016 Heart Failure Guidelines 2016
SGK 2016 Session: Postgraduate Course in Heart Failure Lausanne, 15. June 2016 Heart Failure Guidelines 2016 Matthias Nägele, MD University Hospital Zurich Disclosures I have nothing to disclose. The new
More information2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure Developed in Collaboration With the American Academy of Family Physicians, American College of Chest
More informationXLVII ERA-EDTA / II DGfN Congress Munich, Germany, 26 June 2010
Iron Where and are Anaemia we now Management in managing in anaemia ND-CKD: in patients Where with are we ND-CKD going?? XLVII ERA-EDTA / II DGfN Congress Munich, Germany, 26 June 2010 CHOIR Study NEJM
More informationREVIEWS. Iron deficiency and cardiovascular disease
Iron deficiency and cardiovascular disease Stephan von Haehling, Ewa A. Jankowska, Dirk J. van Veldhuisen, Piotr Ponikowski and Stefan D. Anker Abstract Iron deficiency affects up to one-third of the world
More informationThe Hearth Rate modulators. How to optimise treatment
The Hearth Rate modulators How to optimise treatment Munich, ESC Congress 2012 Prof. Luigi Tavazzi GVM Care&Research E.S. Health Science Foundation Cotignola, IT Disclosure Cooperation with: Servier, Medtronic,
More informationferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharma UK Ltd
Resubmission ferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharma UK Ltd 06 May 2011 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationCongestive Heart Failure: Outpatient Management
The Chattanooga Heart Institute Cardiovascular Symposium Congestive Heart Failure: Outpatient Management E. Philip Lehman MD, MPP Disclosure No financial disclosures. Objectives Evidence-based therapy
More informationNew horizons in HF: potential of new drugs
New horizons in HF: potential of new drugs Marc A. Pfeffer, MD, PhD Dzau Professor of Medicine, Harvard Medical School Cardiovascular Division, Brigham & Women s Hospital Boston, Massachusetts FINANCIAL
More informationSleep Apnea and Heart Failure
Sleep Apnea and Heart Failure Micha T. Maeder, MD Cardiology Division Kantonsspital St. Gallen Switzerland micha.maeder@kssg.ch Sleep Disordered Breathing (SDB) in HFrEF 700 HFrEF patients (LVEF
More informationHighlight Session Heart failure and cardiomyopathies Michel KOMAJDA Paris France
Highlight Session 2014 Heart failure and cardiomyopathies Michel KOMAJDA Paris France # esccongress www.escardio.org/esc2014 HEART FAILURE AND CARDIOMYOPATHIES TOPIC 1 Drug Therapy TOPIC 2 Device Therapy
More informationferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharmaceuticals
ferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharmaceuticals 17 December 2010 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationOptimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure
Optimal blockade of the Renin- Angiotensin-Aldosterone Aldosterone- (RAA)-System in chronic heart failure Jan Östergren Department of Medicine Karolinska University Hospital Stockholm, Sweden Key Issues
More informationANEMIA IN CANCER ROLE OF IV IRON
ANEMIA IN CANCER ROLE OF IV IRON IRON DEFICIENCY Absolute vs functional Absolute iron deficiency µ anemia = no iron stores : ferritin < 20 µg/l in N individual < 100 µg/l in infl/cancer patient Functional
More informationHeart Failure Update. Chim Lang
Heart Failure Update Chim Lang Heart Failure Patient s Journey Acute Treat and stabilize Initiate monitoring Plan interventions Chronic Optimize drug and device therapy Manage Co-morbidities Subacute
More informationConflict of Interest Statement. Pharmacy Technician Objectives. Pharmacist Objectives
Updates to Heart Failure Guidelines: Are you ready to SHIFT into a new PARADIGM? Conflict of Interest Statement I have no actual or potential conflict of interest in relation to this activity Denise M
More informationANEMIA & HEMODIALYSIS
ANEMIA & HEMODIALYSIS The anemia of CKD is, in most patients, normocytic and normochromic, and is due primarily to reduced production of erythropoietin by the kidney and to shortened red cell survival.
More informationST2 in Heart Failure. ST2 as a Cardiovascular Biomarker. Competitive Model of ST2/IL-33 Signaling. ST2 and IL-33: Cardioprotective
ST2 as a Cardiovascular Biomarker Lori B. Daniels, MD, MAS, FACC Professor of Medicine Director, Coronary Care Unit University of California, San Diego ST2 and IL-33: Cardioprotective ST2: member of the
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationIRON DEFICIENCY / ANAEMIA ANTHONY BEETON
IRON DEFICIENCY / ANAEMIA ANTHONY BEETON HYPOXIA 1-2 mg IRON Labile iron Body iron ± 3 4 g Liver and the reticuloendothelial system and spleen (approximately 200 300 mg in adult women and 1 g in adult
More informationHeart failure and co-morbidities
Heart failure and co-morbidities Stefano Taddei Department of Clinical and Experimental Medicine University of Pisa, Italy Declared receipt of grants and contracts from Novartis, Servier, Boehringer Declared
More informationTreatment Of Preserved Cardiac Function Heart Failure with an Aldosterone antagonist (TOPCAT) AHA Nov 18, 2014 Update on Randomized Trials
Treatment Of Preserved Cardiac Function Heart Failure with an Aldosterone antagonist (TOPCAT) AHA Nov 18, 2014 Update on Randomized Trials Marc A. Pfeffer, MD, PhD; Brian Claggett, PhD; Susan F. Assmann,
More informationFrom PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group
From PARADIGM-HF to Clinical Practice Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group PARADIGM-HF: Inclusion Criteria Chronic HF NYHA FC II IV with LVEF
More informationUpdates in Congestive Heart Failure
Updates in Congestive Heart Failure GREGORY YOST, DO JOHNSTOWN CARDIOVASCULAR ASSOCIATES 1/28/2018 Disclosures Edwards speaker on Sapien3 valves (TAVR) Stages A-D and NYHA Classes I-IV Stage A: High risk
More informationCardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes
Biomarkers 2018 Cardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationHeart Failure Update. Bibiana Cujec MD May 2015
Heart Failure Update Bibiana Cujec MD May 2015 Disclosures Participation in clinical trial GUIDE IT (BNP in management of HF) Plan Review of new trials/ccs guidelines Management of heart failure: cases
More informationApproach to Heart Failure in 2018: What Do the Recent Guidelines Tell Us?
Approach to Heart Failure in 2018: What Do the Recent Guidelines Tell Us? Biykem Bozkurt, MD, FACC The Mary and Gordon Cain Chair & Professor of Medicine Medical Care Line Executive, DeBakey VA Medical
More informationSystolic Dysfunction Clinical/Hemodynamic Guide for Management; New Medical and Interventional Therapeutic Challenges
Systolic Dysfunction Clinical/Hemodynamic Guide for Management; New Medical and Interventional Therapeutic Challenges Clyde W. Yancy, MD, MSc, FACC, FAHA, MACP Magerstadt Professor of Medicine Professor,
More informationGUIDELINES FOR ADMINISTRATION OF INTRAVENOUS IRON IN ADULTS WITH CHRONIC KIDNEY DISEASE
GUIDELINES FOR ADMINISTRATION OF INTRAVENOUS IRON IN ADULTS WITH CHRONIC KIDNEY DISEASE Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if
More informationHFA- ESC criteria for Advanced HF and US Requirements for Destination Therapy
HFA- ESC criteria for Advanced HF and US Requirements for Destination Therapy ESC- HFA criteria for Adv-HF Severe symptoms of HF (NYHA class III or IV) with episodes of fluid retention and/or peripheral
More informationPresent and future options in the pharmacological treatment of heart failure
Present and future options in the pharmacological treatment of heart failure Karl Swedberg Professor of Medicine Sahlgrenska Academy University of Gothenburg Gö teborg, Sweden Symptomatic heart failure
More informationClinical Policy: Ferric Carboxymaltose (Injectafer) Reference Number: CP.PHAR.234
Clinical Policy: (Injectafer) Reference Number: CP.PHAR.234 Effective Date: 06/16 Last Review Date: 03/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important
More informationCombination of renin-angiotensinaldosterone. how to choose?
Combination of renin-angiotensinaldosterone system inhibitors how to choose? Karl Swedberg Professor of Medicine Sahlgrenska Academy University of Gothenburg karl.swedberg@gu.se Disclosures Research grants
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationEjection Fraction in Heart Failure: A Redefinition. Tarek Kashour King Fahad Cardiac Center King Saud University Riyadh, KSA
Ejection Fraction in Heart Failure: A Redefinition Tarek Kashour King Fahad Cardiac Center King Saud University Riyadh, KSA Word of caution!!! Incomplete understanding of a disease process may lead to
More informationINIBITORI NEPRILISINA
INIBITORI NEPRILISINA Marco Canepa, MD, PhD Università degli Studi di Genova Cardiologia, Ospedale Policlinico San Martino IRCCS marco.canepa@unige.it ARNI: ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITORS
More informationThe Approach to Patients with Heart Failure and Mid-Range (40-50%) Ejection Fraction (HFmrEF)
The Approach to Patients with Heart Failure and Mid-Range (40-50%) Ejection Fraction (HFmrEF) 22 nd Annual Heart Failure 2018 an Update on Therapy April 21, 2018 Los Angeles, CA Barry Greenberg, M.D. Distinguished
More informationHeart Failure with preserved ejection fraction (HFpEF)
Heart Failure with preserved ejection fraction (HFpEF) Dr. Pierpaolo Pellicori Hull York Medical School Kingston-upon-Hull United Kingdom Conflict of interest: none Heart failure is a contemporary problem
More informationClinical Policy: Ferumoxytol (Feraheme) Reference Number: CP.PHAR.165
Clinical Policy: (Feraheme) Reference Number: CP.PHAR.165 Effective Date: 03/16 Last Review Date: 03/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationHeart.org/HFGuidelinesToolkit
2017 /H/HFS Focused Update of the 2013 F/H 6.3.1 Biomarkers for Prevention: Recommendation OR LOE Recommendation a For patients at risk of developing HF, natriuretic peptide biomarker-based screening followed
More informationHFpEF 2016 : Comorbidities and Outcomes
HFpEF 2016 : Comorbidities and Outcomes Christopher M. O Connor, MD, FACC CEO and Executive Director, Inova Heart and Vascular Institute Professor of Medicine, Duke University Editor in Chief, JACC: Heart
More informationSevere Left Ventricular Dysfunction: Evolving Revascularization Strategies
Severe Left Ventricular Dysfunction: Evolving Revascularization Strategies Robert O. Bonow, MD, MS, MACC Northwestern University Feinberg School of Medicine Bluhm Cardiovascular Institute Northwestern
More informationFREQUENCY OF ANEMIA AND CLINICAL OUTCOME IN PATIENTS WITH CONGESTIVE HEART FAILURE. Malik Faisal Iftekhar, Abdul Sami,Imran Khan, Akhter Sher
Pak Heart J ORIGINAL ARTICLE FREQUENCY OF ANEMIA AND CLINICAL OUTCOME IN PATIENTS WITH CONGESTIVE HEART FAILURE 1 2 3 4 Malik Faisal Iftekhar, Abdul Sami,Imran Khan, Akhter Sher 1-4 Hayatabad Medical Complex,
More informationUpdate on pharmacological treatment of heart failure. Aldo Pietro Maggioni, MD, FESC ANMCO Research Center Firenze, Italy
Update on pharmacological treatment of heart failure Aldo Pietro Maggioni, MD, FESC ANMCO Research Center Firenze, Italy Presenter Disclosures Dr. Maggioni : Serving in Committees of studies sponsored
More informationHF and CRT: CRT-P versus CRT-D
HF and CRT: CRT-P versus CRT-D Andrew E. Epstein, MD Professor of Medicine, Cardiovascular Division University of Pennsylvania Chief, Cardiology Section Philadelphia VA Medical Center Philadelphia, PA
More informationCV Strategies to Mitigate Cardiotoxicity Pharmacologic Therapy Heart Failure Medications and Statins and For How Long
CV Strategies to Mitigate Cardiotoxicity Pharmacologic Therapy Heart Failure Medications and Statins and For How Long Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Albert
More informationI know the trials in heart failure but how do I manage my patient? Dosing of neurohormones antagonists
I know the trials in heart failure but how do I manage my patient? Dosing of neurohormones antagonists Alessandro Fucili (Ferrara, IT) Massimo F Piepoli (Piacenza, IT) Clinical Case: 82 year old woman
More informationSummary of Recommendation Statements Kidney International Supplements (2012) 2, ; doi: /kisup
http://www.kidney-international.org & 2012 KDIGO Summary of Recommendation Statements Kidney International Supplements (2012) 2, 283 287; doi:10.1038/kisup.2012.41 Chapter 1: Diagnosis and evaluation of
More informationClinical Policy: Iron Sucrose (Venofer) Reference Number: CP.PHAR.167
Clinical Policy: (Venofer) Reference Number: CP.PHAR.167 Effective Date: 03/16 Last Review Date: 03/17 Revision Log Coding Implications See Important Reminder at the end of this policy for important regulatory
More information